Summit在近5000万美元的内部收购后反弹

2026-06-13 01:39

Shares of Summit Therapeutics (SMMT) bounced back, recovering recent losses on Friday after the cancer drug developer’s co-CEO Robert Duggan disclosed the purchase of nearly $50M worth of company shares.
According to a regulatory filing on Friday, Duggan purchased more than 3.8M shares of Summit (SMMT) at $13.12 each, raising his stake in the company by about 1% to roughly 573.8M shares. The transaction, valued at nearly $50M, took place on Friday, stated the filing.
Shares of the Florida-based biotech dropped earlier this month after data from a China-based late-stage trial testing its lead asset, ivonescimab, as a first-line therapy for non-small cell lung cancer.
On Thursday, the company withdrew plans to sell $500M worth of shares in an underwritten public offering, citing adverse market conditions.

More on Summit Therapeutics